AbbVie runs ‘Migraine Relief Tok’ calming shorts, but there’s no letup for migraine marketersnews2021-12-17T10:22:02+00:00December 17th, 2021|Fierce Pharma|
AbbVie runs ‘Migraine Relief Tok’ calming shorts, but there’s no letup for migraine marketersnews2021-12-17T10:22:02+00:00December 17th, 2021|Fierce Pharma|
Citing blood clot risks, CDC advisers recommend mRNA pandemic vaccines over J&J shotnews2021-12-16T21:23:24+00:00December 16th, 2021|Fierce Pharma|
Citing blood clot risks, CDC advisers recommend mRNA pandemic vaccines over J&J shotnews2021-12-16T21:23:24+00:00December 16th, 2021|Fierce Pharma|
Pfizer’s peak COVID sales now pegged at $50B-plus, with vaccine still hauling in $25B by 2027: analystsnews2021-12-16T20:50:23+00:00December 16th, 2021|Fierce Pharma|
Pfizer’s peak COVID sales now pegged at $50B-plus, with vaccine still hauling in $25B by 2027: analystsnews2021-12-16T20:50:23+00:00December 16th, 2021|Fierce Pharma|
Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analystnews2021-12-16T16:31:09+00:00December 16th, 2021|Fierce Pharma|
Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analystnews2021-12-16T16:31:09+00:00December 16th, 2021|Fierce Pharma|
Regeneron’s COVID antibody loses effectiveness against omicron, so it’s working on a new versionnews2021-12-16T16:08:37+00:00December 16th, 2021|Fierce Pharma|
Regeneron’s COVID antibody loses effectiveness against omicron, so it’s working on a new versionnews2021-12-16T16:08:37+00:00December 16th, 2021|Fierce Pharma|
